Drug Shortage Report for HYDROMORPHONE HYDROCHLORIDE INJECTION, USP

Last updated on 2022-08-09 History
Report ID 160653
Drug Identification Number 02491699
Brand name HYDROMORPHONE HYDROCHLORIDE INJECTION, USP
Common or Proper name HYDROmorphone Hydrochloride Injection, USP 2 mg/mL SD Vial 1 mL
Company Name FRESENIUS KABI CANADA LTD
Market Status MARKETED
Active Ingredient(s) HYDROMORPHONE HYDROCHLORIDE
Strength(s) 2MG
Dosage form(s) SOLUTION
Route of administration SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR
Packaging size 1mL
ATC code N02AA
ATC description OPIOIDS
Reason for shortage Disruption of the manufacture of the drug.
Anticipated start date
Actual start date 2022-05-06
Estimated end date 2022-08-08
Actual end date 2022-08-08
Shortage status Resolved
Updated date 2022-08-09
Company comments Fresenius Kabi Canada regrets to advise that due to production delays, we will be experiencing a supply interruption on our HYDROmorphone Hydrochloride Injection, USP 2 mg/mL SD Vial 1 mL effective May 6, 2022 until Aug 8, 2022.
Health Canada comments
Tier 3 Status No
Contact Address 165 GALAXY BLVD, SUITE 100
TORONTO, ONTARIO
CANADA M9W 0C8
Company contact information

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v6 2022-08-09 French Compare
v5 2022-08-09 English Compare
v4 2022-07-15 French Compare
v3 2022-07-15 English Compare
v2 2022-05-15 French Compare
v1 2022-05-15 English Compare

Showing 1 to 6 of 6